• About us
• Contact

Advertisement

Organisation › Details

Versant Ventures

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm's emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.4 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm's founding in 1999, more than 95 Versant companies have achieved successful acquisitions or IPOs. *

 

	Start	1999-01-01 established
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Bolzon, Bradley (Brad) (Versant Ventures 200701 Managing Director)
	Person 2	Walmsley, Graham (Logos Capital 201908– General Partner + Managing Partner before Versant Ventures)
	Region	Menlo Park, CA
	Country	United States (USA)
	Street	3000 Sand Hill Road Bldg. 4, Suite 210
	City	94025 Menlo Park, CA
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	5,400,000,000 (capital under management (2023) 2023-11-01)
		* Document for »About Section«: Gate Bioscience, Inc.. (11/1/23). "Press Release: Gate Bioscience Emerges from Stealth and Introduces Molecular Gates, a New Class of Small Molecule Therapeutics". Brisbane, CA.
		Record changed: 2024-02-16

Advertisement

More documents for Versant Ventures

• [1] Firefly Bio, Inc.. (2/15/24). "Press Release: Firefly Bio Debuts with $94 Million Series A Financing". South San Francisco, CA....
• [2] Gate Bioscience, Inc.. (11/1/23). "Press Release: Gate Bioscience Emerges from Stealth and Introduces Molecular Gates, a New Class of Small Molecule Therapeutics". Brisbane, CA....
• [3] CRISPR Therapeutics AG. (3/29/23). "Press Release: CRISPR Therapeutics Announces Departure of Board Member". Zug & Boston, MA....
• [4] Vector BioPharma AG. (8/10/22). "Press Release: Versant Ventures Launches Vector BioPharma AG". Basel....
• [5] Cimeio Therapeutics AG. (4/13/22). "Press Release: Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A". Basel & Boston, MA....
• [6] Stablix, Inc.. (6/3/21). "Press Release: Stablix Therapeutics Launches with $63 Million Series A Financing". New York, NY....
• [7] Graphite Bio. (9/16/20). "Press Release: Graphite Bio Launches with $45 Million Series A Financing". South San Francisco, CA....
• [8] T-Knife GmbH. (8/6/20). "Press Release: T-Knife Completes € 66 Million Series A Financing to Develop Next-Generation T-Cell Therapies". Berlin....
• [9] Versant Ventures. (8/5/20). "Press Release: Versant Ventures Launches Matterhorn Biosciences". Basel....
• [10] Alentis Therapeutics AG. (7/29/20). "Press Release: Alentis Therapeutics Names Roberto Iacone CEO". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.